GlobeNewsWire
11 Jun 2026, 02:10 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to inflate revenue. — Allegations of revenue manipulation through channel stuffing directly attack the integrity of a company's financial reporting and growth claims.
-0.70The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed related party transactions suggest governance failures and potential legal/regulatory liabilities.
-0.50The class action covers a significant period of security purchases between August 9, 2024, and March 25, 2026. — A long class period increases the potential size of the plaintiff group and the eventual financial settlement cost.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is the subject of a securities class action lawsuit alleging channel stuffing and lack of internal controls.
The company is mentioned as the subject of a class action lawsuit filing.
The company is mentioned as the subject of a class action lawsuit filing.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Newsfile Corp
5h ago
